Company intelligence / Profile preview

PanTera

Ownership: Private
Development stage: Other

Overview

PanTera is focused on large-scale production of actinium‑225, a key radioisotope for targeted alpha therapy in oncology. The company’s patented photo-nuclear “gamma” process enables reliable supply of actinium‑225 to support clinical trials and future commercial therapies. No direct clinical results are reported by the company itself as it is an enabler/supplier rather than a therapeutic developer

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalRadiotherapeutic agent (Targeted Alpha Therapy)
Industry: Chemicals & Materials

Partnerships

IBASCK CENEQT Life Sciences

Beyond the preview

Go deeper on PanTera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PanTera.

Explore the full profile